Table 1.
The characteristics of the participants
| Varuables | No-OSAHS (n=47) | Mild-OSAHS (n=51) | Moderate-OSAHS (n=51) | Severe-OSAHS (n=33) | x2/F | p-value |
|---|---|---|---|---|---|---|
| Male [n (%)] | 23 (48.9) | 33 (64.7) | 28 (54.9) | 24 (72.7) | 2.16 | 0.094 |
| Age (years) | 64.5±16.48 | 66.6±13.81 | 68.5±13.58 | 63.0±14.87 | 1.14 | 0.33 |
| BMI (kg/m2) | 22.6±3.12 | 23.7±3.09 | 25.0±3.22 | 27.6±4.46 | 15.37 | 0.001 |
| Smoking [n (%)] | 14 (29.79) | 20 (39.22) | 22 (43.14) | 21 (63.64) | 3.18 | 0.025 |
| Hypertension [n (%)] | 5 (10.64) | 10 (19.61) | 11 (21.57) | 8 (24.24) | 1.14 | 0.33 |
| Hyperlipidemia [n (%)] | 26 (55.32) | 33 (64.71) | 29 (56.86) | 24 (72.73) | 1.06 | 0.37 |
| Diabetes [n (%)] | 12 (25.53) | 17 (33.33) | 14 (27.45) | 17 (51.52) | 2.21 | 0.089 |
| Atrial fibrillation [n (%)] | 12 (25.53) | 10 (19.61) | 24 (47.06) | 18 (54.55) | 6.31 | 0.001 |
| Coronary heart disease [n (%)] | 21 (44.68) | 24 (47.06) | 25 (49.02) | 16 (48.48) | 0.07 | 0.98 |
| Renal insufficiency [n (%)] | 6 (12.77) | 6 (11.76) | 6 (11.76) | 8 (24.24) | 0.28 | 0.84 |
| Heart failure [n (%)] | 11 (23.4) | 10 (19.61) | 30 (58.82) | 14 (42.42) | 0.36 | 0.09 |
| LDL-C (mmol/l) | 2.4±0.76 | 2.2±0.90 | 2.7±1.13 | 2.8±0.98 | 0.61 | 0.61 |
| HDL-C (mmol/l) | 1.2±0.32 | 1.2±0.34 | 1.1±0.30 | 1.1±0.24 | 3.17 | 0.26 |
| TC (mmol/l) | 3.9±1.18 | 3.8±1.11 | 4.9±1.54 | 4.7±1.51 | 5.4 | 0.001 |
| TG (mmol/l) | 1.2±0.77 | 1.3±0.60 | 1.6±0.95 | 1.7±1.50 | 2.94 | 0.035 |
| Lpa (mg/l) | 1.1±0.22 | 1.1±0.20 | 1.1±0.20 | 1.0±0.20 | 0.9 | 0.44 |
| Apoprotein A (mg/l) | 0.74±0.26 | 0.69±0.24 | 0.78±0.34 | 0.74±0.24 | 0.99 | 0.4 |
| Apoprotein B (mg/l) | 223.6±237.78 | 227.3±185.53 | 333.0±262.85 | 335.6±199.48 | 3.49 | 0.017 |
| Glycosylated hemolobin (%) | 6.19±1.32 | 6.28±1.21 | 6.41±1.19 | 6.86±1.56 | 1.82 | 0.15 |
| Uric acid (umol/l) | 400.4±126.98 | 428.5±133.29 | 434.1±127.14 | 451.2±123.32 | 1.12 | 0.34 |
| PCSK9 (ng/ml) | 23.9±24.93 | 61.2±36.80 | 149.2±94.73 | 274.7±61.72 | 128 | 0.001 |
Table 2:
The association between different degrees of OSAHS and PCSK9 levels
| Varuables | Crude Model | Model 1 | Model 2 | |||
|---|---|---|---|---|---|---|
| 95% CI | P-value | 95% CI | P-value | 95% CI | P-value | |
| OSAS | ||||||
| No | Reference | Reference | Reference | |||
| Mild | 1.051(1.028–1.076) | <0.001 | 1.051(1.028–1.077) | <0.001 | 1.051(1.027–1.078) | <0.001 |
| Moderate | 1.065(1.042–1.093) | <0.001 | 1.066(1.042–1.094) | <0.001 | 1.062(1.037–1.090) | <0.001 |
| Severe | 1.083(1.060–1.114) | <0.001 | 1.083(1.060–1.115) | <0.001 | 1.080(1.055–1.113) | <0.001 |
Figure 1.
The association between different degrees of OSAHS and PCSK9 levels
Figure 2.
ROC curve of PCSK9 in predicting OSAHS
Figure 3.
ROC curve of PCSK9 in predicting moderate to severe OSAHS